Corcept Therapeutics Inc (CORT)
22.68
-0.32
(-1.39%)
USD |
NASDAQ |
Apr 18, 16:00
22.66
-0.02
(-0.07%)
After-Hours: 20:00
Corcept Therapeutics Cash from Financing (TTM): -148.72M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -148.72M |
| September 30, 2023 | -149.55M |
| June 30, 2023 | -159.60M |
| March 31, 2023 | -16.60M |
| December 31, 2022 | -17.28M |
| September 30, 2022 | -224.19M |
| June 30, 2022 | -233.87M |
| March 31, 2022 | -257.15M |
| December 31, 2021 | -302.59M |
| September 30, 2021 | -96.28M |
| June 30, 2021 | -66.77M |
| March 31, 2021 | -33.94M |
| December 31, 2020 | 12.21M |
| September 30, 2020 | 12.73M |
| June 30, 2020 | 9.561M |
| March 31, 2020 | -13.15M |
| December 31, 2019 | -28.64M |
| September 30, 2019 | -40.53M |
| June 30, 2019 | -51.50M |
| March 31, 2019 | -31.55M |
| December 31, 2018 | -14.34M |
| September 30, 2018 | 0.263M |
| June 30, 2018 | 6.692M |
| March 31, 2018 | -2.323M |
| December 31, 2017 | -7.953M |
| Date | Value |
|---|---|
| September 30, 2017 | -11.34M |
| June 30, 2017 | -12.27M |
| March 31, 2017 | -7.838M |
| December 31, 2016 | -7.096M |
| September 30, 2016 | -6.468M |
| June 30, 2016 | -5.18M |
| March 31, 2016 | -5.408M |
| December 31, 2015 | 13.07M |
| September 30, 2015 | 12.14M |
| June 30, 2015 | 12.37M |
| March 31, 2015 | 12.53M |
| December 31, 2014 | -3.079M |
| September 30, 2014 | -2.542M |
| June 30, 2014 | -1.671M |
| March 31, 2014 | -1.059M |
| December 31, 2013 | -0.97M |
| September 30, 2013 | -0.174M |
| June 30, 2013 | 76.21M |
| March 31, 2013 | 76.41M |
| December 31, 2012 | 89.57M |
| September 30, 2012 | 89.41M |
| June 30, 2012 | 13.68M |
| March 31, 2012 | 13.72M |
| December 31, 2011 | 42.48M |
| September 30, 2011 | 43.49M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-302.59M
Minimum
Dec 2021
12.73M
Maximum
Sep 2020
-95.05M
Average
-51.50M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
| Ultragenyx Pharmaceutical Inc | 388.14M |
| Alnylam Pharmaceuticals Inc | 172.13M |
| Catalyst Pharmaceuticals Inc | -10.86M |
| United Therapeutics Corp | -11.90M |
| XOMA Corp | 120.59M |